Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuo Miyoshi

Showing results (21-30 of 178) with videos related to

Pageof 18
Sort By:
Breast Cancer Research and Treatment|September 21, 2023
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulinAyako Bun, Masayuki Nagahashi, Mamiko Kuroiwa, et al.
International Journal of Clinical Oncology|January 31, 2026
Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective studyYuri Takamatsu, Yoshiya Horimoto, Yasuo Miyoshi, et al.
Cancer Letters|March 25, 2006
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancerNatsumi Irahara, Yasuo Miyoshi, Tetsuya Taguchi, et al.
International Journal of Cancer|November 16, 2005
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancerNatsumi Irahara, Yasuo Miyoshi, Tetsuya Taguchi, et al.
Journal of Cancer Research and Clinical Oncology|September 25, 2008
Association of loss of BRCA1 expression with centrosome aberration in human breast cancerAtsushi Shimomura, Yasuo Miyoshi, Tetsuya Taguchi, et al.
The Oncologist|November 16, 2023
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 TrialEriko Tokunaga, Yasuo Miyoshi, Koji Dozono, et al.
Breast Cancer (Tokyo, Japan)|January 20, 2005
Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancersYasuo Miyoshi, Tetsuya Taguchi, Seung Jin Kim, et al.
Nagoya Journal of Medical Science|June 20, 2018
Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0Kazuhiro Kitajima, Yasuo Miyoshi, Toshiko Yamano, et al.
Endocrine Research|January 6, 2006
Possible involvement of aromatase overexpression induced by cyclo-oxygenase-2 in the pathogenesis of idiopathic gynecomastiaNatsumi Irahara, Yasuo Miyoshi, Tetsuya Taguchi, et al.
Annals of Nuclear Medicine|November 15, 2017
Prognostic value of FDG-PET and DWI in breast cancerKazuhiro Kitajima, Yasuo Miyoshi, Toshiko Yamano, et al.
Pageof 18

Showing results (21-30 of 178) with videos related to

Sort By:
Pageof 18
Breast Cancer Research and Treatment|September 21, 2023
Baseline interleukin-6 is a prognostic factor for patients with metastatic breast cancer treated with eribulinAyako Bun, Masayuki Nagahashi, Mamiko Kuroiwa, et al.
International Journal of Clinical Oncology|January 31, 2026
Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective studyYuri Takamatsu, Yoshiya Horimoto, Yasuo Miyoshi, et al.
Cancer Letters|March 25, 2006
Quantitative analysis of aromatase, sulfatase and 17beta-HSD(1) mRNA expression in soft tissue metastases of breast cancerNatsumi Irahara, Yasuo Miyoshi, Tetsuya Taguchi, et al.
International Journal of Cancer|November 16, 2005
Quantitative analysis of aromatase mRNA expression derived from various promoters (I.4, I.3, PII and I.7) and its association with expression of TNF-alpha, IL-6 and COX-2 mRNAs in human breast cancerNatsumi Irahara, Yasuo Miyoshi, Tetsuya Taguchi, et al.
Journal of Cancer Research and Clinical Oncology|September 25, 2008
Association of loss of BRCA1 expression with centrosome aberration in human breast cancerAtsushi Shimomura, Yasuo Miyoshi, Tetsuya Taguchi, et al.
The Oncologist|November 16, 2023
Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 TrialEriko Tokunaga, Yasuo Miyoshi, Koji Dozono, et al.
Breast Cancer (Tokyo, Japan)|January 20, 2005
Prediction of response to docetaxel by immunohistochemical analysis of CYP3A4 expression in human breast cancersYasuo Miyoshi, Tetsuya Taguchi, Seung Jin Kim, et al.
Nagoya Journal of Medical Science|June 20, 2018
Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0Kazuhiro Kitajima, Yasuo Miyoshi, Toshiko Yamano, et al.
Endocrine Research|January 6, 2006
Possible involvement of aromatase overexpression induced by cyclo-oxygenase-2 in the pathogenesis of idiopathic gynecomastiaNatsumi Irahara, Yasuo Miyoshi, Tetsuya Taguchi, et al.
Annals of Nuclear Medicine|November 15, 2017
Prognostic value of FDG-PET and DWI in breast cancerKazuhiro Kitajima, Yasuo Miyoshi, Toshiko Yamano, et al.
Pageof 18